Formulation Development
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Propanc Biopharma, Inc. recently announced a plan to acquire $100 million of Ethereum over the next 12 months. The asset purchase of Ethereum will enhance…
Olema Oncology Announces New Clinical Trial Agreement With Pfizer
Olema Pharmaceuticals, Inc. recently announced a new clinical trial collaboration and supply agreement with Pfizer Inc. in metastatic breast cancer. The companies will evaluate in…
Zenas BioPharma & Royalty Pharma Enter Obexelimab Funding Agreement for up to $300 Million
Zenas BioPharma, Inc. and Royalty Pharma plc recently announced Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on…
Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy Designation Granted by FDA for ETX101 in SCN1A+ Dravet Syndrome
Encoded Therapeutics Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ETX101 following review of preliminary seizure data from…
Step Pharma Announces First Participant Dosed in a Phase 1b Trial of Dencatistat for Essential Thrombocythaemia
Step Pharma recently announced the first participant has been dosed with its lead asset dencatistat in a phase 1b clinical trial for essential thrombocythaemia (ET).…
OMass Therapeutics Enters Exclusive Collaboration & License Agreement With Genentech
OMass Therapeutics recently announced it has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialize OMass’ preclinical…
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure & Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75
Lexicon Pharmaceuticals, Inc. recently announced a post-hoc analysis (Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF) of clinical data was…
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Esperion welcomed the inclusion of bempedoic acid as the only non-statin newly recommended for LDL-C lowering and cardiovascular risk reduction in the 2025 Focused Update…
TOLREMO Therapeutics Receives Two FDA Fast Track Designations
TOLREMO therapeutics AG recently announced its lead candidate, TT125-802, received two Fast Track designations from the US FDA for the treatment of non-small cell lung…
Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy
Wugen, Inc. recently announced the closing of $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital,…
TREOS Bio Partners With Charité Berlin & Junshi Biosciences to Launch Pivotal Phase 2 Clinical Trial in Refractory MSS Colorectal Cancer
TREOS Bio Ltd. recently announced the execution of clinical collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences for the initiation of OBERTO-202, a…
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
MannKind Corporation recently announced United Therapeutics Corporation has exercised its option—granted under the companies’ 2018 license and collaboration agreement—to develop a second dry powder inhalation…
Moleculin Issues New Positive AML Overall Survival Data
Moleculin Biotech, Inc. recently announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as Ara-C and…
Bio-Rad Expands Range of StarBright Dyes to Enhance Panel Design Capabilities for Spectral Flow Cytometry
Bio-Rad Laboratories, Inc. recently announced the introduction of a new range of StarBright Dyes, providing greater choice and flexibility for spectral flow cytometry in immunology…
Cereno Scientific Granted FDA Fast Track Designation for CS1 in Rare Disease Pulmonary Arterial Hypertension
Cereno Scientific recently announced the US FDA has granted Fast Track designation to its lead program, CS1, for the treatment of pulmonary arterial hypertension (PAH).…
Hongene to Supply exNA Oligonucleotide Technology Under New Licensing Deal
Hongene Biotech Corporation recently entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and…
Scenic Enters License & Research Agreement With Alnylam
Scenic Biotech recently announced a license and research agreement with Alnylam Pharmaceuticals, Inc. to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.…
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Allarity Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The…
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery
Clearside Biomedical, Inc. recently announced its SCS delivery platform and CLS-AX program will be highlighted in multiple presentations at the 25th EURETINA Congress from September…
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
CDT Equity Inc. recently announced it has successfully identified a new biological target and novel therapeutic indication for its lead program, AZD1656 (and its derivatives),…
